Toll-like receptor 4 - Lymphocyte antigen 96 complex (TLR4-MD-2)

The Toll-like receptor 4 - Lymphocyte antigen 96 complex (TLR4-MD-2) is a fundamental pattern recognition receptor of the innate immune system, primarily responsible for detecting lipopolysaccharide (LPS) from Gram-negative bacteria [1][2]. MD-2 (Lymphocyte antigen 96) is an essential co-receptor that non-covalently associates with the extracellular domain of TLR4 and contains a deep hydrophobic pocket that accommodates the lipid A moiety of LPS [1][5]. Upon LPS binding, the complex undergoes a conformational change that promotes the dimerization of two TLR4-MD-2-LPS units, initiating intracellular signaling through MyD88-dependent and TRIF-dependent pathways [3][4]. This signaling cascade leads to the activation of transcription factors such as NF-kappaB and the subsequent release of pro-inflammatory cytokines like TNF-alpha and IL-6 [3]. While essential for host defense, dysregulated or excessive activation of the TLR4-MD-2 complex is a major driver of systemic inflammatory response syndrome (SIRS), sepsis, and various chronic inflammatory or autoimmune disorders [4][6]. Consequently, the LPS-binding pocket of MD-2 is a high-priority target for the development of therapeutic antagonists, such as Eritoran, designed to competitively inhibit LPS binding and mitigate life-threatening inflammation [3]. (References: [1] Park et al., Nature 2009; [2] Shimazu et al., J Exp Med 1999; [3] O'Neill et al., Pharmacol Rev 2009; [4] UniProt O00206; [5] UniProt Q9Y6Y9; [6] StatPearls Sepsis)

Other names

TLR4/MD2CD284/LY96Myeloid differentiation factor 2 - Toll-like receptor 4 complexLPS receptor complexToll-like receptor 4 - MD-2 complex

Competitive antagonism of the LPS-binding pocket in MD-2, inhibition of TLR4-MD-2 dimerization, and blockade of downstream MyD88 and TRIF signaling pathways.